Boundless Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $44.8M | $55.3M | $42.6M | — |
| Operating expenses | $63.6M | $73.3M | $54.8M | — |
| Operating income | -$63.6M | -$73.3M | -$54.8M | — |
| Income tax expense | $0 | $0 | — | — |
| Net income | -$58.2M | -$65.4M | -$49.4M | — |
| Balance Sheet | ||||
| Cash and equivalents | $17.9M | $26.6M | $23.7M | — |
| Current assets | $109.6M | $154.4M | $124.2M | — |
| Total assets | $157.1M | $206.4M | $129.9M | — |
| Current liabilities | $12.5M | $8.1M | $9.4M | — |
| Total liabilities | $58.4M | $55.8M | $9.4M | — |
| Stockholders' equity | $98.7M | $150.6M | -$127.1M | -$81.7M |
| Cash Flow Statement | ||||
| Cash from operations | -$46.7M | -$60.8M | -$46.9M | — |
| Depreciation and amortization | $1.3M | $1.1M | $957,000 | — |
| Stock-based compensation | $6.1M | $7.5M | $3.3M | — |
| Capital expenditure | $546,000 | $2.5M | $633,000 | — |
| Free cash flow | -$47.2M | -$63.4M | -$47.5M | — |
Shares outstanding 22.5M · Free float 59.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.